Abstract: High concentrations of lactate are considered to contribute to impairment of the peritoneal membrane. We investigated the longer-period effects of bicarbonate/ lactate-buffered neutral peritoneal dialysis fluid (PDF) in patients undergoing PD for about 2 years. Patients undergoing PD were changed from a lactate-buffered neutral PDF to a bicarbonate/lactate-buffered neutral PDF. We then investigated the patients' clinical outcomes and peritoneal membrane functions as well as the surrogate markers in the drained dialysate. Fourteen patients undergoing PD were enrolled. Peritonitis was observed in one patient. No other adverse events were observed. Peritoneal function did not change as the ultrafiltration volume decreased. Fibrin degradation products and vascular endothelial growth factor in the drained dialysate decreased while the interleukin level increased. These results suggest that bicarbonate/lactatebuffered neutral PDF may have beneficial effects in terms of peritoneal preservation and can be safely used in patients undergoing PD.
Peritoneal dialysis (PD) is a home-based renal replacement therapy in patients with end-stage renal disease (1) . In PD, the peritoneal membrane is used as a semipermeable membrane for solute transport and ultrafiltration (1) . PD has several advantages over hemodialysis, such as maintaining residual renal function and enabling a better quality of life without the need to become bedridden for treatment (2, 3) . However, a major obstacle to long-term PD is the structural and functional deleterious changes in the peritoneal membrane (4) (5) (6) . These changes are caused by repeated exposure of the peritoneal membrane to bioincompatible PD fluid (PDF) (4) (5) (6) . Among the factors in PDF, glucose degradation products generated from high concentrations of glucose for increased osmolarity, acidic conditions (pH of 4.5-5.5) to enable decreased glucose degradation and high concentrations of lactate (40 mEq/L) for correction of metabolic acidosis in patients undergoing PD have been considered to contribute to impairment of the peritoneal membrane (7) (8) (9) . To overcome these problems, a new PDF containing a decreased level of lactate (10 mEq/L), physiological level of bicarbonate (25 mEq/L), and fewer glucose degradation products at a neutral pH (6.6-7.5) (bicarbonate/lactate-buffered neutral PDF) has been developed. We previously reported the beneficial effects of bicarbonate/lactate-buffered neutral PDF for peritoneal preservation in the short term (3 months) in patients undergoing PD (10) . However, its longerperiod effects have not been clarified. In this study, we investigated the longer-period effects of bicarbonate/ lactate-buffered neutral PDF and peritoneal preservation in patients undergoing PD for 21 months.
MATERIALS AND METHODS

Experimental methods and design
This study was an extension of our previous study, which was performed to investigate the effects of bicarbonate/lactate-buffered neutral PDF on peritoneal preservation in the short term (3 months) in patients undergoing PD (10) . This study was performed in accordance with the Declaration of Helsinki and approved by the ethics committee of Saitama Medical Center, Jichi Medical University. Written informed consent was obtained from all patients.
Study population
The inclusion criteria were an age of ≥20 years and current treatment by PD with lactate-buffered neutral PDF. The exclusion criteria were an exit-site or tunnel infection of the PD catheter, a peritonitis episode within the previous 3 months, and the presence of malignant disease, systemic inflammatory disease, or current immunosuppressive therapy. The further details of the study population are described in our previous report (10) .
PDF
The bicarbonate/lactate-buffered neutral PDFs used in this study were Reguneal-HCa and Reguneal-LCa (Baxter Limited Japan, Tokyo, Japan). The lactate-buffered neutral PDFs used in this study were Dianeal-N PD-2 and Dianeal-N PD-4 (Baxter Limited Japan). The compositions of the bicarbonate/lactate-buffered neutral PDF and lactate-buffered neutral PDF are summarized in Table 1 .
Study design
This was a single-center prospective observational study of the longer-period (21-month) effects of bicarbonate/lactate-buffered neutral PDF. All eligible patients undergoing PD who agreed to participate in this study in our hospital were enrolled. A diagram of the study design is shown in Figure 1 . Details of the study design are described in our previous report (10) . Briefly, the enrolled patients were changed from existing lactate-buffered neutral PDF (Dianeal-N PD-2 or Dianeal-N PD-4) to bicarbonate/lactate-buffered neutral PDF (Reguneal-HCa or Reguneal-LCa) with the same composition of glucose, electrolytes, and fluid volume but different bicarbonate and lactate concentrations. The PDFs for automated PD were not changed for about 1 year because the bag systems for Reguneal-HCa and Reguneal-LCa were not available for our automated PD system. About 1 year later, some patients changed from lactate-buffered neutral PDFs to bicarbonate/lactatebuffered neutral PDFs for automated PD. Icodextrincontaining PDF (Extraneal; Baxter Limited Japan) was not changed to control ultrafiltration. PD prescription and medications had been adjusted according to patients' conditions since 4 months or later after changing PDF.
Clinical outcomes and peritoneal preservation
The total mortality rate, admission rate, PD withdrawal rate, and adverse events were investigated during the study period. To estimate the effects of the bicarbonate/lactate-buffered neutral PDF on peritoneal preservation, a peritoneal equilibration test (PET) was performed within 1 month before changing the PDF, at 2 to 3 months after changing the PDF, and every 6 months thereafter. Changes in the surrogate markers of peritoneal membrane failure such as fibrin degradation products (FDP), vascular endothelial growth factor (VEGF), cancer antigen 125 (CA125), interleukin-6 (IL-6), and transforming growth factor beta 1 (TGF-β 1 ) in the drained dialysate were investigated when the PET was performed. The changes in the serum levels of bicarbonate and lactate, the pH, and the anion gap were investigated at same time as the PET. The anion gap was also analyzed at the same time as the PET and calculated with the following formula (11):
PET and other laboratory tests The details of PET and other laboratory tests are described in our previous report (10) . Briefly, drainage of the intra-abdominal fluid was followed by an intraperitoneal injection of 2 L of PDF containing 2.5% glucose. The creatinine (Cr) level of the peritoneal effluents obtained 4 h after the injection (D) was divided by the Cr level of plasma (P) to obtain the D/P Cr ratio. The glucose level of the peritoneal effluents obtained 4 h after the injection (D) was divided by that obtained immediately after injection (D0) to obtain the D/D0 glucose ratio. The ultrafiltration was calculated by the volumes of peritoneal effluents obtained 4 h after the injection minus injection volumes plus sample volume. The FDP, VEGF, IL-6, CA125, and TGF-β 1 levels were analyzed by a clinical chemistry laboratory (SRL, Tokyo, Japan). Blood samples were analyzed by the chemical laboratory in Saitama Medical Center, Jichi Medical University.
Statistical analysis
Data are expressed as mean AE standard deviation. The means of the indicated groups were compared using repeated-measures analysis of variance. If statistical significance was detected, Bonferroni's test was performed as a post hoc analysis to compare the means of the two different groups. A P-value of <0.05 was considered statistically significant.
RESULTS
Patient characteristics
The patients' baseline characteristics are shown in Table 2 . Fourteen patients (7 male, 7 female; age, 64.1 AE 7.7 years) were enrolled in this study. The initial volume of lactate-buffered PDF including Extraneal was 6.0 AE 1.4 L/day. The daily volume of lactate-buffered neutral PDF (4.0 AE 1.6 L/day) was changed by the same volume of bicarbonate/ lactate-buffered neutral PDF (Table 2) . Although PD prescription and medications adjusted according to patients' conditions since 4 months or later after changing PDF, the total daily volume of PDFs and the bicarbonate/lactate-buffered PDF were not significantly changed between at 3 months and at 21 months (Table 2) .
Clinical outcomes
During the observation period, the total mortality rate was 0.0% (0/14 patients), the admission rate associated with PD was 21.4% (3/14 patients; 2 with infection of the tunneled PD catheter, 1 with volume overload), and the PD withdrawal rate was 0.0% (0/14 patients). One patient with a tunneled catheter infection recovered by administration of antibiotic reagents, and the other patient required a PD catheter replacement operation. Peritonitis was observed in one patient, but he recovered by antibiotic therapy without admission. No other adverse events, including severe hypertension or hypotension, severe acidosis, or abnormalities of electrolyte Data are presented as mean AE standard deviation, n, or n (%). CAPD, continuous ambulatory peritoneal dialysis; CCPD, continuous cycling peritoneal dialysis; PD, peritoneal dialysis; PDF, peritoneal dialysis fluid. levels or glucose metabolism, were observed during the study period. The serum bicarbonate level and pH were significantly decreased with use of the bicarbonate/lactate-buffered neutral PDF (Fig. 2) . The serum lactate level and anion gap did not change with use of the bicarbonate/lactate-buffered
FIG. 2.
Effects of bicarbonate/lactate-buffered neutral PDF on serum bicarbonate and lactate levels, pH, and anion gap. PDF, peritoneal dialysis fluid; NS, not significant; *P < 0.05. neutral PDF (Fig. 2) . As shown in Table 3 , other clinical and laboratory parameters including body weight, blood pressure, and serum levels of Cr, blood urea nitrogen, albumin, total protein, and electrolytes did not change with use of the bicarbonate/lactate-buffered neutral PDF during the study period.
Peritoneal preservation
The D/P Cr ratio and D/D0 glucose ratio did not change, but the ultrafiltration volume had significantly decreased at 21 months (Fig. 3) . The FDP and VEGF levels in the drained dialysate significantly decreased but the IL-6 level in the drained dialysate significantly increased with use of the bicarbonate/lactate-buffered neutral PDF (Fig. 4) . The CA125 level in the drained dialysate did not change with use of the bicarbonate/lactate-buffered neutral PDF (Fig. 4) . The change in the TGF-β 1 level in the drained dialysate could not be analyzed because it was detected in the peritoneal effluent of only one patient.
DISCUSSION
In the present study, bicarbonate/lactate-buffered neutral PDF that had been changed from lactatebuffered PDF decreased various surrogate markers of peritoneal membrane impairment in the drained dialysate, such as FDP and VEGF, in the patients undergoing PD without severe complications for the longer term. These results suggest that bicarbonate/ lactate-buffered neutral PDF may have beneficial effects on peritoneal preservation and can be used safely in patients undergoing PD. Clinical outcomes such as death and withdrawal from PD were not observed. Although admissions due to two cases of tunnel PD catheter infections and one case of volume overload were observed, all three patients recovered by treatment including administration of antibiotic agents, PD catheter replacement, and diuretics. One patient with peritonitis recovered by administration of antibiotic agents without admission. No other severe complications were observed with the use of bicarbonate/ lactate-buffered neutral PDF in the patients undergoing longer-period PD in the present study. The serum bicarbonate level and pH decreased with use of the bicarbonate/lactate-buffered neutral PDF, and the former fall within reference interval and the latter were maintained at the physiologic level during the study period. It previously demonstrated that serum bicarbonate level rose by 1.5 mEq/L when patients were switched from a 35 mEq/L lactate PDF to a 25 mEq/L bicarbonate/10 mEq/L lactate mixed PDF (total buffer 35 mEq/L) (12) , but in the present study the buffer was decreased from a 40 mEq/L lactate to a 25 mEq/L bicarbonate/10 mEq/L lactate (total 35 mEq/L) and therefore serum bicarbonate level might decreased. Additionally, the serum lactate level and anion gap did not change. These results suggest that bicarbonate/lactate-buffered neutral PDF can be used safely and can correct metabolic alkalosis to within reference interval in patients undergoing longer-period PD.
Long-term PD causes deleterious structural and functional changes in the peritoneal membrane by repeated exposure of the membrane to bioincompatible PDF (4) (5) (6) . Therefore, the development of biocompatible PDF with beneficial effects for peritoneal membrane preservation is important to improve the prognosis of patients undergoing PD. In this study, the peritoneal membrane function as determined by the PET (D/P Cr ratio, D/D0 glucose ratio) did not change with a decreased ultrafiltration volume using the bicarbonate/lactate-buffered neutral PDF in patients undergoing longer-period PD
FIG. 4.
Effects of bicarbonate/lactate-buffered neutral PDF on biomarkers of peritoneal membrane impairment in drained dialysate. The effects of bicarbonate/lactate-buffered neutral PDF and lactate-buffered neutral PDF on FDP, VEGF, CA125, and IL-6 levels are shown. FDP, fibrin degradation products; VEGF, vascular endothelial growth factor; CA125, cancer antigen 125; IL-6, interleukin-6; PDF, peritoneal dialysis fluid; NS, not significant; *P < 0.05.
(21 months). Additionally, the PDF decreased surrogate markers of peritoneal membrane impairment in the drained dialysate, such as FDP and VEGF, in patients undergoing longer-period PD. VEGF in peritoneal effluents reportedly increases vascular permeability and angiogenesis in the peritoneal membrane, resulting in peritoneal membrane impairment (13, 14) . The FDP level in the peritoneal effluent has been considered to reflect chronic inflammation of the peritoneum (15-17). Therefore, the FDP level of the peritoneal effluent may serve as a marker of peritoneal membrane impairment (15) (16) (17) (18) . VEGF and FDP in the drained dialysate decreased with use of the bicarbonate/lactatebuffered neutral PDF. These results suggest that bicarbonate/lactate-buffered neutral PDF may have beneficial effects on peritoneal membrane function in patients undergoing longer-period PD. The IL-6 level in the drained dialysate increased with use of the bicarbonate/lactate-buffered neutral PDF. IL-6 is a pleiotropic cytokine with both pro-inflammatory and anti-inflammatory properties (19) . Several studies have reported that an increased intraperitoneal IL-6 level was associated with peritoneal inflammation; thus, the IL-6 level in the peritoneal effluent may be a predictor of peritoneal membrane failure (20) . However, other studies have shown that preservation of the mesothelial cell mass and peritoneal membrane may contribute to increased IL-6 levels and improved host defense capability in patients undergoing PD (21, 22) . Therefore, a further study to determine the clinical significance of the increased IL-6 level in the drained dialysate with use of the bicarbonate/lactate-buffered neutral PDF described in the present study is necessary.
This study has two main limitations. First, it was a single-arm study without a control group; therefore, we could not confirm whether bicarbonate/lactatebuffered neutral PDF is superior for patients undergoing PD with respect to peritoneal preservation or the acid-base balance than conventional PDFs such as lactate-buffered neutral PDFs. Second, the sample size was small. Further long-term comparative studies will be required to evaluate the effects of bicarbonate/lactate-buffered neutral PDF in patients undergoing PD.
CONCLUSIONS
The bicarbonate/lactate-buffered neutral PDF decreased the levels of surrogate markers of peritoneal membrane impairment in the drained dialysate in patients undergoing longer-period PD without severe complications. These results suggest that bicarbonate/lactate-buffered neutral PDF may have beneficial effects on peritoneal preservation and can be used safely in patients undergoing longer-period PD.
